ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.177,62
-0,90%
S&P 500
5.469,30
0,39%
Dow Jones
39.112,16
-0,76%
Euro vs US Dollar
1,07105
-0,20%
Bitcoin
61.674,20
2,34%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Regencell Bioscience Holdings Ltd (RGC)

  7. Regencell Bioscience Holdings Ltd (RGC) News

RGC

Regencell Bioscience (RGC)

Regencell Bioscience Holdings Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:RGC
DatumZeitQuelleÜberschriftSymbolFirma
20/06/202415h13Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RGCRegencell Bioscience Holdings Ltd
02/01/202412h04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RGCRegencell Bioscience Holdings Ltd
15/12/202312h09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RGCRegencell Bioscience Holdings Ltd
27/10/202322h15Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:RGCRegencell Bioscience Holdings Ltd
15/06/202322h01Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:RGCRegencell Bioscience Holdings Ltd
05/06/202312h07Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:RGCRegencell Bioscience Holdings Ltd
17/03/202311h04Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:RGCRegencell Bioscience Holdings Ltd
28/02/202315h16Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:RGCRegencell Bioscience Holdings Ltd
04/01/202314h01Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:RGCRegencell Bioscience Holdings Ltd
22/12/202213h01Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:RGCRegencell Bioscience Holdings Ltd
31/10/202221h18Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:RGCRegencell Bioscience Holdings Ltd
12/09/202215h18Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:RGCRegencell Bioscience Holdings Ltd
12/09/202215h15Business WireRegencell Bioscience’s Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy TrialNASDAQ:RGCRegencell Bioscience Holdings Ltd
26/07/202214h34Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:RGCRegencell Bioscience Holdings Ltd
07/06/202217h37ValueWalkGame-Stop Or Game-On? RGC Has It All And Twice MoreNASDAQ:RGCRegencell Bioscience Holdings Ltd
02/06/202222h17Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:RGCRegencell Bioscience Holdings Ltd
18/05/202214h05Business WireRegencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment PeriodNASDAQ:RGCRegencell Bioscience Holdings Ltd
18/05/202213h58Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:RGCRegencell Bioscience Holdings Ltd
16/05/202214h56Business WireRegencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEONASDAQ:RGCRegencell Bioscience Holdings Ltd
16/05/202213h02Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:RGCRegencell Bioscience Holdings Ltd
16/05/202213h00Business WireRegencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEONASDAQ:RGCRegencell Bioscience Holdings Ltd
16/05/202212h51Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:RGCRegencell Bioscience Holdings Ltd
26/04/202214h08Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:RGCRegencell Bioscience Holdings Ltd
04/04/202213h31Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:RGCRegencell Bioscience Holdings Ltd
30/12/202122h06Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:RGCRegencell Bioscience Holdings Ltd
15/12/202115h49Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:RGCRegencell Bioscience Holdings Ltd
13/12/202114h31Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:RGCRegencell Bioscience Holdings Ltd
17/11/202123h01Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:RGCRegencell Bioscience Holdings Ltd
29/10/202114h32Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:RGCRegencell Bioscience Holdings Ltd
07/09/202122h06Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:RGCRegencell Bioscience Holdings Ltd
 Showing the most relevant articles for your search:NASDAQ:RGC

Kürzlich von Ihnen besucht

NASDAQ
GIPR
Generation Income Proper...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten